Product Description
Riluzole is a benzothiazole derivative which inhibits glutamatergic neurotransmission and blocks voltage-dependent sodium channels (ED₅₀ = 2.3 μM). It reduces the uptake of GABA from neuronal synapse. Riluzole suppresses glutamate-induced seizures in rats with an ED₅₀ value of 3.2 mg/kg and displays neuroprotective effects in hypoxic animals with an ED₅₀ value of 4 mg/kg. It is used for the treatment of amyotrophic lateral sclerosis.
Riluzole is a benzothiazole derivative which inhibits glutamatergic neurotransmission and blocks voltage-dependent sodium channels (ED₅₀ = 2.3 μM). It reduces the uptake of GABA from neuronal synapse. Riluzole suppresses glutamate-induced seizures in rats with an ED₅₀ value of 3.2 mg/kg and displays neuroprotective effects in hypoxic animals with an ED₅₀ value of 4 mg/kg. It is used for the treatment of amyotrophic lateral sclerosis.
Biovision | B3068 | Riluzole DataSheet
Alternate Name/Synonyms: Rilutek; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; 2-Amino-6-(trifluoromethoxy)benzothiazole; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine
Appearance: White to light yellow powder
Formulation:
CAS Number: 1744-22-5
Structure Available?: TRUE
Peptide sequence:
Salt Form: FALSE
Molecular Formula: C₈H₅F₃N₂OS
Molecular Weight: 234.2
Cell-Permeable?: TRUE
Purity: ≥98%
Solubilities: ~25 mg/ml in DMSO
Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Country of Origin: USA
Tag Line: An inhibitor of glutamatergic neurotransmission
MDL Number: MFCD00210213
PubChem CID: 5070
SMILES: C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
InChi: InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
InChi Key: FTALBRSUTCGOEG-UHFFFAOYSA-N